Nuvigene

Nuvigene Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation gene therapies. The company leverages a proprietary AAV vector platform to create treatments for ophthalmic and central nervous system disorders. Its lead program, NVG-101, is an investigational gene therapy for wet age-related macular degeneration designed to reduce the burden of frequent intravitreal injections. Nuvigene's approach focuses on optimizing capsid engineering and expression cassettes to improve therapeutic efficacy and safety. The company is backed by prominent venture capital firms and maintains integrated R&D and GMP manufacturing capabilities.